



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

18 March 2022
EMA/CVMP/126530/2022
Committee for Veterinary Medicinal Products

Summary of opinion¹ (post-authorisation)

Advocate

International non-proprietary name (INN): imidacloprid / moxidectin

On 16 March 2022, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion², recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Advocate. The marketing authorisation holder for this veterinary medicinal product is Bayer Animal Health GmbH.

Advocate is currently authorised as spot-on solution in cats, ferrets and dogs suffering from, or at risk from, mixed parasitic infections. The variation concerns the addition of a new therapeutic indication for the treatment of the lungworm *Troglostrongylus brevior* (adults) in cats. Also, the applicant takes the opportunity to make some editorial amendments to the package leaflet.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

